Biblio
“Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
, “Cognitive Profile and its Association with Neuroimaging Markers of Non-Demented Cerebral Amyloid Angiopathy Patients in a Stroke Unit.”, J Alzheimers Dis, vol. 52, no. 1, pp. 171-8, 2016.
, “Cognitive Stimulation Modulates Platelet Total Phospholipases A2 Activity in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 957-62, 2016.
, “Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden.”, J Alzheimers Dis, vol. 50, no. 2, pp. 387-96, 2016.
, “Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.”, J Alzheimers Dis, vol. 53, no. 1, pp. 1-14, 2016.
, “Comparing the Effects of Multisensory Stimulation and Individualized Music Sessions on Elderly People with Severe Dementia: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 303-15, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Comparison of Prefrontal Atrophy and Episodic Memory Performance in Dysexecutive Alzheimer's Disease and Behavioral-Variant Frontotemporal Dementia.”, J Alzheimers Dis, vol. 51, no. 3, pp. 889-903, 2016.
, “Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimer's Disease: Opening the Conversation to Prepare Ethical Responses.”, J Alzheimers Dis, vol. 51, no. 1, pp. 1-9, 2016.
, “Concanavalin agglutinin levels are decreased in peripheral blood of Alzheimer's disease patients.”, J Alzheimers Dis, vol. 49, no. 1, pp. 63-72, 2016.
, “Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost.”, J Alzheimers Dis, vol. 49, no. 2, pp. 277-85, 2016.
, “Course and Determinants of Anosognosia in Alzheimer's Disease: A 12-Month Follow-up.”, J Alzheimers Dis, vol. 51, no. 2, pp. 357-66, 2016.
, “Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1161-8, 2016.
, “The Cytome Assay as a Tool to Investigate the Possible Association Between Exposure to Extremely Low Frequency Magnetic Fields and an Increased Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 741-9, 2016.
, “Decreased Inter-Hemispheric Functional Connectivity in Cognitively Intact Elderly APOE ɛ4 Carriers: A Preliminary Study.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1137-48, 2016.
, “Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.”, J Alzheimers Dis, vol. 50, no. 1, pp. 101-10, 2016.
, “Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach.”, J Alzheimers Dis, vol. 51, no. 2, pp. 427-37, 2016.
, “Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles.”, J Alzheimers Dis, vol. 49, no. 3, pp. 593-605, 2016.
, “Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 3, pp. 743-54, 2016.
, “Detection of Alzheimer's Disease by Three-Dimensional Displacement Field Estimation in Structural Magnetic Resonance Imaging.”, J Alzheimers Dis, vol. 50, no. 1, pp. 233-48, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
, “Diagnostic Assessment and Management of Dysphagia in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 947-55, 2016.
, “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
,